Sands Capital Management
TSHA icon

Sands Capital Management’s Taysha Gene Therapies TSHA Stock Holding History

Sands Capital Management’s Portfolio TSHA Stock Details TSHA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-724,873
Closed -$15.4M – 77
2021
Q2 		$15.4M Hold
724,873
– – 0.03% 71
2021
Q1 		$14.7M Sell
724,873
-95,567
-12% -$2.59M 0.03% 70
2020
Q4 		$21.8M Hold
820,440
– – 0.04% 73
2020
Q3 		$17.7M Buy
+820,440
New +$19.3M 0.04% 73

Other funds holding TSHA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
UOTTAIMCU
University of Texas/Texas AM Investment Management Co (UTIMCO) Austin, Texas $687M AUM 21.33% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCV
Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return
TCM
TimesSquare Capital Management New York $5.89B AUM 28.74% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return

Sands Capital Management's TSHA Position: Q3 2021 in Review

Sands Capital Management sold out of Taysha Gene Therapies (TSHA) in Q3 2021, closing a stake of 724,873 shares — an estimated $15.4M sold.

Sands Capital Management first reported a position in TSHA in Q3 2020 and held it in 4 quarters. The position peaked at $21.8M in Q4 2020. 48 funds tracked by Wall St. Rank hold TSHA as of Q3 2021.

  • Sands Capital Management reported no remaining Taysha Gene Therapies position as of Q3 2021 after selling out during the quarter.
  • Sands Capital Management sold 724,873 Taysha Gene Therapies shares in Q3 2021, an estimated $15.4M.
  • Sands Capital Management first reported a position in Taysha Gene Therapies in Q3 2020 and held it in 4 quarters.
  • Sands Capital Management's Taysha Gene Therapies position peaked at $21.8M in Q4 2020.
  • 48 funds tracked by Wall St. Rank held Taysha Gene Therapies as of Q3 2021.

Based on Sands Capital Management's 13F filing for Q3 2021, filed 3 Nov 2021.